Gisondi P, Geat D, Mattiucci A, et al. - Among patients suffering from non-small-cell lung cancer (NSCLC), researchers performed this prospective observational study to examine the incidence, effect on treatment as well as management of epidermal growth factor receptor (EGFR) inhibitor-related cutaneous reactions. They analyzed 87 consecutive patients that had advanced NSCLC and were managed with EGFR-tyrosine kinase inhibitors from January to December 2019. The presence of cutaneous reactions was seen in 71 patients (81.6%). Acneiform eruptions (56.3%), xerosis ± asteatotic eczema (48.3%), nail changes (39.1%), mucositis (29.9%), pruritus (24.1%) and hair changes (12.6%) were the most commonly seen. A higher rate of nail changes and mucositis was noted in relation to afatinib vs other agents. No patient-associated predictive factors were found. Benefits were seen with a multidisciplinary approach to EGFR inhibitor-related cutaneous reactions and can lower the requirement to discontinue oncologic treatment.